Hard To Treat Diseases (HTDS) Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger
HTDS and Slavica Biochem are also discussing on expanding the research topics to include other applications from the field of regenerative medicine. The newly discussed project would be dealing with a method for treatment of damaged articular cartilage – the autologous implantation of in vitro cultivated chondrocytes (the cells which form the cartilage). This new technique is one of the most important orthopaedic achievements of this century. As aforementioned the research team from Slavica BioChem www.slavicabiochem.com is considering a merger with the bio company from one of the EU countries where this technology is already being deployed. The HTDS management does not wish to disturb its current share structure in the merger discussions. One alternative solution currently being explored by the management is to license this technology and to use HTDS own cash resources and low labour costs in Serbia to launch both enterprises in Serbia. The company would generate revenues with the export throughout western
Marker Reports and similar research studies indicate that stem cell and regenerative medicine is a
A medical research report of the autologous chondrocytes project is filed with Pink Sheets www.pinksheets.com under the “Filings Tab”.
HTDS operates two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. www.mellowhope.com. Slaivca’s primary focus involves the enhancement and modification of existing approved drugs such as “Virazole” for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatis C. Mellow Hope is
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hard to Treat Diseases